133 related articles for article (PubMed ID: 31362839)
21. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
Lederhandler M; Beasley JM; Brinster NK; Nagler AR
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677801
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
23. Anaphylaxis preceded by erythema multiforme with sorafenib: First case report.
Mantovani A; Álvares-Da-Silva MR
Ann Hepatol; 2019; 18(5):777-779. PubMed ID: 31085038
[TBL] [Abstract][Full Text] [Related]
24. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M
Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907
[TBL] [Abstract][Full Text] [Related]
25. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
26. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
27. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Ponziani FR; Bhoori S; Germini A; Bongini M; Flores M; Sposito C; Facciorusso A; Gasbarrini A; Mazzaferro V
Liver Int; 2016 Jul; 36(7):1033-42. PubMed ID: 26709844
[TBL] [Abstract][Full Text] [Related]
28. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi M; Okusaka T
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):407-417. PubMed ID: 28497756
[TBL] [Abstract][Full Text] [Related]
29. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
33. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
34. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
[TBL] [Abstract][Full Text] [Related]
35. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
36. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
37. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
[TBL] [Abstract][Full Text] [Related]
38. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
